BioNTech SE

BioNTech SE reported a net loss of $1.14 billion for fiscal year 2025, with comprehensive loss of $1.25 billion. Despite the net loss, the company generated positive operating cash flow of $456.0 million, primarily driven by working capital improvements including a $1.08 billion decrease in trade receivables and contract assets. The balance sheet remains strong with total assets of $21.99 billion, including $7.68 billion in cash and cash equivalents and $7.20 billion in other financial assets. Total equity stands at $19.22 billion with retained earnings of $17.96 billion. Investing activities consumed $2.47 billion in cash, mainly from $11.42 billion in investments in other financial assets, partially offset by $9.51 billion in proceeds from maturities. The company's financial position remains robust despite the reported net loss, with significant liquidity and investment capacity.

Key Takeaways